Tesamorelin: Stabilized GHRH — Complete Analysis
Educational Content Only
The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
⚠️ The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.
Scientific guide to Tesamorelin: FDA-approved GHRH analogue for HIV lipodystrophy, mechanism of action on GH/IGF-1 axis, visceral fat reduction and evidence from EGRIFTA trials.
Mechanism of Action
Tesamorelin is a synthetic analogue of human GHRH (44 amino acids), modified with addition of a trans-3-hexenoic acid group at the N-terminus for stability. It is the only FDA-approved GHRH analogue (Egrifta®) for treatment of abdominal lipodystrophy in HIV+ patients. It acts directly on the pituitary GHRH-R receptor.
GHRH-R Binding and cAMP Signaling
Tesamorelin binds to the GHRH-R receptor on pituitary somatotroph cells with high specificity. Binding activates Gs protein → adenylate cyclase → cAMP → PKA → CREB phosphorylation → GH1 gene transcription → GH synthesis and exocytosis. The effect is physiological: maintains normal pulsatile GH pattern.
IGF-1 Increase and Visceral Lipolysis
Elevated GH stimulates hepatic IGF-1 synthesis. In visceral adipose tissue, GH activates GHR receptor → JAK2/STAT5 → hormone-sensitive lipase (HSL) expression → preferential lipolysis of visceral adipocytes. This mechanism explains Tesamorelin's specificity for visceral fat (not subcutaneous) observed in clinical trials.
- •Only GHRH analogue with FDA approval (Egrifta® / Egrifta SV®)
- •Level I evidence for visceral fat reduction in HIV lipodystrophy: –15 to –18% visceral fat vs. placebo
- •Emerging data in cognition: amyloid beta reduction in adults with mild cognitive impairment (MCI)
Applications Described in Literature
Abdominal Lipodystrophy in HIV (FDA-approved indication)
High evidencePrimary approved indication. Phase III trials (Falutz et al., NEJM 2007; N=412) demonstrated –15.2% reduction in visceral fat (assessed by DEXA) with Tesamorelin 2 mg/day SC versus placebo after 26 weeks. No significant change in subcutaneous fat. Approved for HIV+ adults on antiretroviral therapy with abdominal fat accumulation.
Cognition and Alzheimer's Disease (emerging research)
Preliminary evidenceEmerging data from clinical trials (Baker et al., 2021, JAMA Neurology) with 152 adults with MCI or mild Alzheimer's demonstrated that Tesamorelin 1 mg/day SC for 20 weeks reduced CSF amyloid beta-42 burden and improved cognition in specific genetic subgroups (APOE ε4+). Hypothetical mechanism: elevated IGF-1 facilitates amyloid clearance and reduces phosphorylated tau.
Body Composition and Metabolic Syndrome (off-label)
Moderate evidenceExploratory studies in HIV-negative adults with central obesity and metabolic syndrome show reductions in visceral fat, triglycerides, and CRP. Literature describes –17% reduction in visceral fat over 26 weeks. Dyslipidemia data shows 10–15% reduction in triglycerides. Off-label use not approved; favorable safety profile in non-diabetic adults.
Relevant Studies
2 curated studies · 2007–2021
Peer-reviewed evidence with PMID verifiable on PubMed
Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation
Falutz J, Allas S, et al. · New England Journal of Medicine
Phase III trial published in NEJM (N=412): Tesamorelin 2 mg/day SC reduced visceral fat by 15.2% vs. 1.4% placebo after 26 weeks. Basis for FDA approval. Favorable tolerability; no clinically significant increase in insulin resistance.
Tesamorelin Reduces Amyloid Burden in Adults With Mild Cognitive Impairment and Low IGF-1
Baker LD, Cotman CW, et al. · JAMA Neurology
RCT (N=152): Tesamorelin 1 mg/day for 20 weeks reduced CSF amyloid beta-42 and improved working memory in adults with MCI and low baseline IGF-1. Greatest benefit in APOE ε4 carriers. Promising finding for neuromodulation via GH/IGF-1 axis.
Latest literature review: 2026-04 · PubMed
FAQ
What is Tesamorelin?
Tesamorelin (EGRIFTA®) is a synthetic GHRH analogue with a trans-3-hexenoic acid modification at the N-terminal portion that increases its stability. It is the only FDA-approved GHRH analogue (2010), indicated for visceral fat reduction in adults with HIV lipodystrophy, with evidence from phase III studies.
What is the difference between Tesamorelin and CJC-1295?
Both are GHRH analogues, but with distinct profiles: Tesamorelin has FDA approval for a specific indication (HIV lipodystrophy) with published phase III studies. CJC-1295 is a synthetic GHRH analogue without regulatory approval, with data predominantly from phase I/II studies. Direct comparison between the two is limited in literature.
Coming Soon
The premium guide for Tesamorelin will be available soon.
Already available: Ipamorelin, BPC-157, Semaglutide, GHK-Cu
View Available Peptides →⚠️ Exclusively educational content. Does not constitute medical prescription.